By Nick Paul Taylor – Fierce Biotech –
Biotech bank balances were again in focus Monday morning, with Tango Therapeutics cutting preclinical work to stretch its cash runway and Avalo Therapeutics outlining options for preserving its money.
Tango extended its cash runway from the third quarter of 2026 to the first quarter of 2027 by narrowing its focus. The biotech said the extension “was primarily due to reduction of preclinical pipeline, target discovery efforts and the associated research headcount.” Tango’s deferral of clinical combination studies to assess tolerability of TNG462 with standard-of-care agents was another factor.
The changes cement the importance of TNG462 to the company’s prospects. Tango is testing the PRMT5 inhibitor in a phase 1/2 trial that is due to deliver data in the second half of the year. The biotech plans to use the data to inform a registrational trial in pancreatic cancer, which is slated for next year, and to guide the next steps in non-small cell lung cancer.
